★★★★☆
3.2 étoiles sur 5 de 559 commentaires client
1999-12-01
Expediting Drug & Biologics Development: A Strategic Approach - de Steven E. Linberg (Author)
Details Expediting Drug & Biologics Development: A Strategic Approach
La ligne ci-dessous contient les informations générales du Expediting Drug & Biologics Development: A Strategic Approach
| Le Titre Du Livre | Expediting Drug & Biologics Development: A Strategic Approach |
| Date de publication | 1999-12-01 |
| Traducteur | Ramzy Pessy |
| Nombre de Pages | 167 Pages |
| Taille du fichier | 68.43 MB |
| Langage | Anglais & Français |
| Éditeur | Hutchinson |
| ISBN-10 | 0129861975-KRB |
| Format de Document | AMZ PDF EPub AWW NBP |
| Auteur | Steven E. Linberg |
| ISBN-13 | 399-2395026133-KLB |
| Nom de Fichier | Expediting-Drug-&-Biologics-Development-A-Strategic-Approach.pdf |
Télécharger Expediting Drug & Biologics Development: A Strategic Approach Livre PDF Gratuit
Expediting Drug Biologics Development 3rd Ed Chapter 3 – Basic Project Management © 2004 Gus Cicala Project Assistants All Rights Reserved Page 1 Overvi…
Noté 005 Retrouvez Expediting Drug Biologics Development A Strategic Approach et des millions de livres en stock sur Achetez neuf ou doccasion
Noté 005 Retrouvez Expediting Drugs and Biologics Development A Strategic Approach 2006 et des millions de livres en stock sur Achetez neuf ou doccasion
Consulter les détails du profil et des missions pour loffre demploi Director Expert in Statistical Methodology chez AstraZeneca
Découvrez et achetez Biosimilar and Interchangeable Biologics Livraison en Europe à 1 centime seulement
Eurofins Amatsigroup is a leading international Contract Development and Manufacturing Organization CDMO headquartered in France Within Eurofins Amatsigroup we provide highquality customized and costeffective drug development solutions integrated under one roof to small biotech and major bio pharmaceutical customers
Expedited Development Review of New Drugs LI 1 Expedited Development Review of New Drugs Jason E Moore MS MBA RAC Regulatory Affairs Roundtable 2